Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag in Elderly AML Patients Receiving Induction Chemotherapy
NCT03603795Phase 2Active, not recruiting
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Oct 2018
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Eltrombopag Arm with Placebo Arm (2 arms). Primary endpoint: Overall Survival Rate at 12 months. Started Oct 2018; status: active, not recruiting.
02
Drugs
eltrombopag
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03603795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603795.